Neoantigen Targeted Therapies in Combination with Immune Checkpoint Inhibitors: Learnings from Novel Clinical Data

Time: 3:30 pm
day: Day One


  • Heterologous prime/boost vaccination utilizing a Chimpanzee Adenoviral vector prime, and a self-amplifying RNA (samRNA) boost drives robust neoantigen specific T-cell responses
  • Less is more: Lower doses of samRNA boost superior T-cell responses than high dose samRNA
  • Neoantigen specific T-cell responses provide therapeutic benefit to patients with  advanced stage MSS-CRC